By Dov Fox The Guardian and L.A. Times are the latest major news organizations to decry trans-Atlantic restrictions on blood donation by men who have sex with men (MSM). The case against such categorical bans has been reignited by an influential piece that Bill of Health editor Glenn Cohen recently published with co-authors Jeremy Feigenbaum and Eli Adashi in the Journal of the American Medical Association. Cohen,…
By Christine Baugh As we enter into the fall sports season, it’s unlikely that a week will go by where we don’t hear the current buzzword in sports community: concussion. Whether in reference to an acute player injury, an untimely death, new or ongoing litigation, or rule changes in sport, the athletic community and…
By Nicolas Terry Julie Donohue, The Impact and Evolution of Medicare Part D, N Engl J Med Lois Shepherd, The End of End-of-Life Law, SSRN/North Carolina L.Rev. Frank Pasquale, Private Certifiers and Deputies in American Health Care, SSRN/NC L. Rev. Peter J. Neumann et al, Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold, N…
By Arthur Caplan Art Caplan has a new video on Medscape laying out the principles behind rationing limited supplies of experimental ebola treatments. As he explains: I believe the answer to the question of who should receive the drug is: people we can both learn from and potentially help the most. I believe those are the 2 values…
By Kevin Outterson A short article in the New Yorker on my favorite topic – business models for antibiotic use and innovation.
By Rachel Sachs On Friday, the Defense Advanced Research Projects Agency (DARPA) announced a challenge to the public: provide the most accurate forecast of the spread of chikungunya virus in each of the countries in the Pan American Health Organization, win $150,000. Innovation prizes like DARPA’s are increasing in popularity, with public and private entities…
By Arthur Caplan Art Caplan has a series of new opinion pieces out on the WHO ethics advisory committee meeting that approved the use of experimental drugs to treat patients ill with Ebola. He suggests deeper exploration of issues of informed consent, corporate responsibility, and resource allocation in this blog post for The Health Care…
By Arthur Caplan Amidst news from Spain that a 75-year-old Catholic priest has received the experimental treatment ZMapp for Ebola, Art Caplan critiques what he describes as the “bad science” behind choosing its recipients: ZMapp is not the answer to the Ebola epidemic ravaging West Africa. There is no chance of getting a significant amount of this drug…
By Ross D. Silverman Earlier this week, the World Health Organization, responding both to the international outcry over the rapidly rising number of Ebola cases and deaths across sub-Saharan Africa (and critiques of the speed of their action), and the news that western health care workers and ministry had found ways to get access to…
By Arthur Caplan As the WHO announced today that medical ethicists will convene next week in New York to discuss the use of experimental medicines in the West African Ebola outbreak, Art Caplan has a timely new opinion piece in the Washington Post asking why only white American victims of the Ebola outbreak have been treated with an experimental…
